BridgeMD
New treatment option for Postoperative Bleeding
Official title Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty
ClinicalTrials.gov ID: NCT06208267
What this study is testing
What is Tranexamic acid?
Tranexamic acid is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for postoperative bleeding.
Also referred to as CYKLOKAPRON.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty. The efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- ° All adults undergoing primary TKA and THA at St-Mary's Hospital
You likely can't join if
- Age \< 18 years
- Known hypersensitivity or allergy to TXA
- Previous history of thromboembolic disease
- Active malignancy (all current cancers other than local skin cancer)
- Significant renal disease (hematuria, dialysis, kidney transplant)
- History of convulsions
See the full eligibility criteria
- ° All adults undergoing primary TKA and THA at St-Mary's Hospital
- Age \< 18 years
- Known hypersensitivity or allergy to TXA
- Previous history of thromboembolic disease
- Active malignancy (all current cancers other than local skin cancer)
- Significant renal disease (hematuria, dialysis, kidney transplant)
- History of convulsions
- Known defective colour vision
- Inability or unwillingness to use MyMobility app
- Unable to communicate in French or English
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.